Chicago Equity Partners LLC Has $791,000 Holdings in Biogen Inc. (BIIB)

Chicago Equity Partners LLC trimmed its position in shares of Biogen Inc. (NASDAQ:BIIB) by 9.6% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,915 shares of the biotechnology company’s stock after selling 310 shares during the quarter. Chicago Equity Partners LLC’s holdings in Biogen were worth $791,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Wrapmanager Inc. increased its holdings in shares of Biogen by 7.7% during the first quarter. Wrapmanager Inc. now owns 5,525 shares of the biotechnology company’s stock valued at $1,511,000 after acquiring an additional 396 shares in the last quarter. Savant Capital LLC increased its holdings in shares of Biogen by 3.7% during the first quarter. Savant Capital LLC now owns 846 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 30 shares in the last quarter. Botty Investors LLC increased its holdings in shares of Biogen by 75.0% during the second quarter. Botty Investors LLC now owns 11,232 shares of the biotechnology company’s stock valued at $3,048,000 after acquiring an additional 4,812 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Biogen by 2.4% during the first quarter. Vanguard Group Inc. now owns 14,352,490 shares of the biotechnology company’s stock valued at $3,924,258,000 after acquiring an additional 342,568 shares in the last quarter. Finally, BB&T Securities LLC increased its holdings in shares of Biogen by 25.0% during the second quarter. BB&T Securities LLC now owns 12,989 shares of the biotechnology company’s stock valued at $3,524,000 after acquiring an additional 2,598 shares in the last quarter. 87.26% of the stock is owned by institutional investors and hedge funds.

Shares of Biogen Inc. (NASDAQ BIIB) opened at 329.69 on Wednesday. Biogen Inc. has a 52 week low of $244.28 and a 52 week high of $329.95. The firm has a market capitalization of $69.71 billion, a P/E ratio of 21.63 and a beta of 0.77. The firm has a 50 day moving average price of $294.57 and a 200-day moving average price of $277.13.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.36 by $0.68. Biogen had a return on equity of 37.42% and a net margin of 28.10%. The business had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $2.81 billion. During the same period in the prior year, the business earned $5.21 earnings per share. The business’s revenue was up 6.4% on a year-over-year basis. Equities research analysts predict that Biogen Inc. will post $21.44 EPS for the current fiscal year.

Several equities analysts have recently issued reports on BIIB shares. Vetr downgraded shares of Biogen from a “strong-buy” rating to a “buy” rating and set a $319.53 price objective on the stock. in a report on Tuesday, August 29th. ValuEngine upgraded shares of Biogen from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. Mizuho cut their price objective on shares of Biogen from $290.00 to $274.00 and set a “neutral” rating on the stock in a report on Wednesday, May 31st. Cowen and Company restated an “outperform” rating and set a $271.00 price objective on shares of Biogen in a report on Monday, July 3rd. Finally, William Blair restated an “outperform” rating on shares of Biogen in a report on Monday, June 26th. Twelve analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $329.95.

WARNING: This report was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/2888211/chicago-equity-partners-llc-has-791000-holdings-in-biogen-inc-biib.html.

In other news, EVP Susan H. Alexander sold 7,758 shares of the company’s stock in a transaction on Wednesday, July 19th. The stock was sold at an average price of $285.00, for a total value of $2,211,030.00. Following the sale, the executive vice president now directly owns 27,232 shares in the company, valued at $7,761,120. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Susan H. Alexander sold 4,974 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $290.01, for a total value of $1,442,509.74. Following the completion of the sale, the executive vice president now owns 22,258 shares in the company, valued at $6,455,042.58. The disclosure for this sale can be found here. 0.32% of the stock is owned by corporate insiders.

Biogen Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.